Proteolytic Processing of Angiotensin-I in Human Blood Plasma

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Hildebrand, Diana ^a   Merkel, Philipp ^a   Eggers, Lars Florian ^a   Schlüter, Hartmut ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN I; CARBOXYPEPTIDASE; MICROSOMAL AMINOPEPTIDASE;

AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD ANALYSIS; CARBOXY TERMINAL SEQUENCE; ENZYME BLOOD LEVEL; HUMAN; IMMUNOFLUORESCENCE TEST; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SECRETION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANGIOTENSIN I; ANGIOTENSINS; ANIMALS; ANTIGENS, CD13; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IMMOBILIZED PROTEINS; MALE; MICE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDYL-DIPEPTIDASE A; PROTEASE INHIBITORS; PROTEOLYSIS; RECOMBINANT PROTEINS;

MAMMALIA;

EID: 84878379400     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064027     Document Type: Article

References (46)

1. Fyhrquist F, Saijonmaa O, (2008) Renin-angiotensin system revisited. J Intern Med 264: 224-236.
2. Capettini LS, Montecucco F, Mach F, Stergiopulos N, Santos RA, et al. (2012) Role of renin-angiotensin system in inflammation, immunity and aging. Curr Pharm Des 18: 963-970.
3. Kranzhofer R, Browatzki M, Schmidt J, Kubler W, (1999) Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 257: 826-828.
4. Campbell-Boswell M, Robertson AL Jr, (1981) Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol 35: 265-276.
5. Gard PR, Naylor C, Ali S, Partington C, (2012) Blockade of pro-cognitive effects of angiotensin IV and physostigmine in mice by oxytocin antagonism. Eur J Pharmacol 683: 155-160.
6. Wright JW, Harding JW, (2013) The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases. Pflugers Arch 465: 133-51.
7. Urata H, Nishimura H, Ganten D, (1996) Chymase-dependent angiotensin II forming systems in humans. Am J Hypertens 9: 277-284.
8. Welches WR, Brosnihan KB, Ferrario CM, (1993) A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci 52: 1461-1480.
9. Jackman HL, Massad MG, Sekosan M, Tan F, Brovkovych V, et al. (2002) Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension. 39: 976-981.
10. Dupont AG, Brouwers S, (2010) Brain angiotensin peptides regulate sympathetic tone and blood pressure. J Hypertens 28: 1599-1610.
11. von Bohlen und Halbach O, (2003) Angiotensin IV in the central nervous system. Cell Tissue Res 311: 1-9.
12. Chappell MC, Brosnihan KB, Diz DI, Ferrario CM, (1989) Identification of angiotensin-(1-7) in rat brain. Evidence for differential processing of angiotensin peptides. J Biol Chem 264: 16518-16523.
13. Neves LA, Almeida AP, Khosla MC, Santos RA, (1995) Metabolism of angiotensin I in isolated rat hearts. Effect of angiotensin converting enzyme inhibitors. Biochem Pharmacol 50: 1451-1459.
14. Champion HC, Garrison EA, Estrada LS, Potter JM, Kadowitz PJ, (1996) Analysis of responses to angiotensin I and angiotensin I-(3-10) in the mesenteric vascular bed of the cat. Eur J Pharmacol 309: 251-259.
15. Garrison EA, Kadowitz PJ, (1996) Analysis of responses to angiotensin I-(3-10) in the hindlimb vascular bed of the cat. Am J Physiol 270: H1172-1177.
16. Kaye AD, Nossaman BD, Smith DE, Ibrahim IN, Anwar M, et al. (1998) Analysis of responses to angiotensin I (3-10) and Leu3 angiotensin (3-8) in the pulmonary vascular bed of the cat. Am J Ther 5: 295-302.
17. Takai S, Sakaguchi M, Jin D, Yamada M, Kirimura K, et al. (2001) Different angiotensin II-forming pathways in human and rat vascular tissues. Clin Chim Acta 305: 191-195.
18. Velez JC, Ierardi JL, Bland AM, Morinelli TA, Arthur JM, et al. (2012) Enzymatic processing of angiotensin peptides by human glomerular endothelial cell. Am J Physiol Renal Physiol 302: F1583-1594.
19. Trusch M, Bohlick A, Hildebrand D, Lichtner B, Bertsch A, et al. (2010) Application of displacement chromatography for the analysis of a lipid raft proteome. J Chromatogr B Analyt Technol Biomed Life Sci 878: 309-314.
20. Schluter H, Jankowski J, Rykl J, Thiemann J, Belgardt S, et al. (2003) Detection of protease activities with the mass-spectrometry-assisted enzyme-screening (MES) system. Anal Bioanal Chem 377: 1102-1107.
21. Brena BM, Batista-Viera F (2006) Immobilization of Enzymes and Cells (Methods in Biotechnology). New Jersey: © Humana Press Inc. 464 p.
22. Ward PE, Benter IF, Dick L, Wilk S, (1990) Metabolism of vasoactive peptides by plasma and purified renal aminopeptidase M. Biochem Pharmacol. 40: 1725-1732.
23. Reaux A, Fournie-Zaluski MC, David C, Zini S, Roques BP, et al. (1999) Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci USA 96: 13415-13420.
24. Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, Corvol P, et al. (1996) Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci USA 93: 11968-11973.
25. Wright JW, Harding JW, (2011) Brain renin-angiotensin-a new look at an old system. Prog Neurobiol 95: 49-67.
26. Bader M, Ganten D, (2008) Update on tissue renin-angiotensin systems. J Mol Med (Berl) 86: 615-621.
27. Velez JC, Ryan KJ, Harbeson CE, Bland AM, Budisavljevic MN, et al. (2009) Angiotensin I is largely converted to angiotensin (1-7) and angiotensin (2-10) by isolated rat glomeruli. Hypertension 53: 790-797.
28. Sim MK, Qiu XS, (1994) Formation of des-Asp-angiotensin I in the hypothalamic extract of normo- and hypertensive rats. Blood Press 3: 260-264.
29. Cole KR, Kumar S, Trong HL, Woodbury RG, Walsh KA, et al. (1991) Rat mast cell carboxypeptidase: amino acid sequence and evidence of enzyme activity within mast cell granules. Biochemistry 30: 648-655.
30. Barrett AJ, Starkey PM, (1973) The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J 133: 709-724.
31. Heeb MJ, Espana F, (1998) alpha2-macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein. Blood Cells Mol Dis 24: 412-419.
32. Lew RA, Warner FJ, Hanchapola I, Yarski MA, Manohar J, et al. (2008) Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol 93: 685-693.
33. Velloso EP, Vieira R, Cabral AC, Kalapothakis E, Santos RA, (2007) Reduced plasma levels of angiotensin-(1-7) and renin activity in preeclamptic patients are associated with the angiotensin I- converting enzyme deletion/deletion genotype. Braz J Med Biol Res. 40: 583-590.
34. Bluher M, Kratzsch J, Paschke R, (2001) Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care 24: 328-334.
35. Jalil JE, Palomera C, Ocaranza MP, Godoy I, Roman M, et al. (2003) Levels of plasma angiotensin-(1-7) in patients with hypertension who have the angiotensin-I-converting enzyme deletion/deletion genotype. Am J Cardiol 92: 749-751.
36. Kappelgaard AM, Nielsen MD, Giese J, (1976) Measurement of angiotensin II in human plasma: technical modifications and practical experience. Clin Chim Acta 67: 299-306.
37. Reyes-Engel A, Morcillo L, Aranda FJ, Ruiz M, Gaitan MJ, et al. (2006) Influence of gender and genetic variability on plasma angiotensin peptides. J Renin Angiotensin Aldosterone Syst 7: 92-97.
38. Lalu K, Lampelo S, Nummelin-Kortelainen M, Vanha-Perttula T, (1984) Purification and partial characterization of aminopeptidase A from the serum of pregnant and non-pregnant women. Biochim Biophys Acta 789: 324-333.
39. Favaloro EJ, Browning T, Facey D, (1993) CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated. Exp Hematol 21: 1695-1701.
40. Tokioka-Terao M, Hiwada K, Kokubu T, (1984) Purification and characterization of aminopeptidase N from human plasma. Enzyme 32: 65-75.
41. Scherberich JE, Wiemer J, Herzig C, Fischer P, Schoeppe W, (1990) Isolation and partial characterization of angiotensinase A and aminopeptidase M from urine and human kidney by lectin affinity chromatography and high-performance liquid chromatography. J Chromatogr 521: 279-289.
42. Palmieri FE, Ward PE, (1989) Dipeptidyl(amino)peptidase IV and post proline cleaving enzyme in cultured endothelial and smooth muscle cells. Adv Exp Med Biol 247A: 305-311.
43. Inoue T, Kanzaki H, Imai K, Narukawa S, Higuchi T, et al. (1994) Bestatin, a potent aminopeptidase-N inhibitor, inhibits in vitro decidualization of human endometrial stromal cells. J Clin Endocrinol Metab 79: 171-175.
44. Garcia Del Rio C, Smellie WS, Morton JJ, (1981) des-Asp-angiotensin I: its identification in rat blood and confirmation as a substrate for converting enzyme. Endocrinology 108: 406-412.
45. Li Q, Feenstra M, Pfaffendorf M, Eijsman L, van Zwieten PA, (1997) Comparative vasoconstrictor effects of angiotensin II, III, and IV in human isolated saphenous vein. J Cardiovasc Pharmacol 29: 451-456.
46. Padia SH, Kemp BA, Howell NL, Siragy HM, Fournie-Zaluski MC, et al. (2007) Intrarenal aminopeptidase N inhibition augments natriuretic responses to angiotensin III in angiotensin type 1 receptor-blocked rats. Hypertension 49: 625-630.